Minerva Neurosciences, Inc. Payments to Acquire Marketable Securities
Minerva Neurosciences, Inc. (NERV) reported Payments to Acquire Marketable Securities of $55.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-07
- Minerva Neurosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $9.83M.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $45.29M.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for fiscal 2020 was $3.87M, a 93.66% decline from fiscal 2019.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for fiscal 2019 was $61.09M, a 50.25% increase from fiscal 2018.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for fiscal 2018 was $40.66M, a 69.77% decline from fiscal 2017.
- Minerva Neurosciences, Inc. payments to acquire marketable securities for fiscal 2017 was $134.53M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $55.13M 10-Q · filed 2026-08-07 | ||
| 2026-03-31 | $45.29M 10-Q · filed 2026-05-05 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $3.87M 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $3.87M 10-Q · filed 2021-11-08 | $15.52M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $3.87M 10-Q · filed 2021-08-02 | $15.52M derived: sum of 3 quarters · filed 2021-08-02 | $31.78M derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-03-31 | $3.87M 10-Q · filed 2021-05-12 | $15.52M derived: sum of 2 quarters · filed 2021-05-12 | $31.78M derived: sum of 3 quarters · filed 2021-05-12 | $45.41M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $27.91M derived: sum of 2 quarters · filed 2021-03-08 | $41.54M derived: sum of 3 quarters · filed 2021-03-08 | $61.09M 10-K · filed 2021-03-08 |
| 2019-09-30 | $16.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $29.90M derived: sum of 2 quarters · filed 2020-11-02 | $49.45M 10-Q · filed 2020-11-02 | $82.17M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-06-30 | $13.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $33.18M 10-Q · filed 2020-08-03 | $65.91M derived: sum of 3 quarters · filed 2020-08-03 | $65.91M derived: sum of 4 quarters · filed 2020-08-03 |
| 2019-03-31 | $19.55M 10-Q · filed 2020-05-04 | $52.28M derived: sum of 2 quarters · filed 2020-05-04 | $52.28M derived: sum of 3 quarters · filed 2020-05-04 | $52.28M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | $32.73M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $32.73M derived: sum of 2 quarters · filed 2020-03-09 | $32.73M derived: sum of 3 quarters · filed 2020-03-09 | $40.66M 10-K · filed 2020-03-09 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $0.00 derived: sum of 2 quarters · filed 2019-11-04 | $7.93M 10-Q · filed 2019-11-04 | $7.91M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $7.93M 10-Q · filed 2019-08-05 | $7.91M derived: sum of 3 quarters · filed 2019-08-05 | $115.09M derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | $7.93M 10-Q · filed 2019-05-06 | $7.91M derived: sum of 2 quarters · filed 2019-05-06 | $115.09M derived: sum of 3 quarters · filed 2019-05-06 | $125.98M derived: sum of 4 quarters · filed 2019-05-06 |
| 2017-12-31 | -$28.53K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $107.16M derived: sum of 2 quarters · filed 2018-11-05 | $118.05M derived: sum of 3 quarters · filed 2018-11-05 | $134.53M 10-K · filed 2018-03-12 |
| 2017-09-30 | $107.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $118.08M derived: sum of 2 quarters · filed 2018-11-05 | $134.55M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $10.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $27.37M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $16.48M 10-Q · filed 2018-05-03 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $116.71K derived: sum of 2 quarters · filed 2018-03-12 | $23.28M 10-K · filed 2018-03-12 | |
| 2015-09-30 | $116.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $23.28M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $23.16M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |